Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | hydroxysteroid (11-beta) dehydrogenase 1 | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Mycobacterium tuberculosis | Probable oxidoreductase | Get druggable targets OG5_132866 | All targets in OG5_132866 |
Mycobacterium ulcerans | short chain dehydrogenase | Get druggable targets OG5_132866 | All targets in OG5_132866 |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Plasmodium falciparum | steroid dehydrogenase, putative | hydroxysteroid (11-beta) dehydrogenase 1 | 292 aa | 250 aa | 24.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Plasmodium vivax | enoyl-acyl carrier protein reductase | 0.3854 | 1 | 1 |
Mycobacterium ulcerans | short chain dehydrogenase | 0.0338 | 0.0812 | 0.0214 |
Trichomonas vaginalis | hypothetical protein | 0.3854 | 1 | 0.5 |
Echinococcus multilocularis | nuclear factor of activated T cells 5 | 0.014 | 0.0295 | 0.4838 |
Mycobacterium ulcerans | short-chain type dehydrogenase/reductase | 0.0266 | 0.0623 | 0.0013 |
Toxoplasma gondii | enoyl-acyl carrier reductase ENR | 0.3854 | 1 | 1 |
Leishmania major | oxidoreductase-like protein | 0.0266 | 0.0623 | 1 |
Mycobacterium ulcerans | enoyl-(acyl carrier protein) reductase | 0.3854 | 1 | 1 |
Schistosoma mansoni | dihydropteridine reductase | 0.0261 | 0.061 | 1 |
Loa Loa (eye worm) | retinol dehydrogenase 12 | 0.0261 | 0.061 | 1 |
Mycobacterium ulcerans | short chain dehydrogenase | 0.0266 | 0.0623 | 0.0013 |
Schistosoma mansoni | 3-oxoacyl-[ACP] reductase | 0.0261 | 0.061 | 1 |
Loa Loa (eye worm) | oxidoreductase | 0.0261 | 0.061 | 1 |
Loa Loa (eye worm) | 3-hydroxyacyl-CoA dehydrogenase type II | 0.0261 | 0.061 | 1 |
Mycobacterium tuberculosis | Probable oxidoreductase | 0.0266 | 0.0623 | 0.0013 |
Onchocerca volvulus | 0.0266 | 0.0623 | 1 | |
Mycobacterium tuberculosis | NADH-dependent enoyl-[acyl-carrier-protein] reductase InhA (NADH-dependent enoyl-ACP reductase) | 0.3854 | 1 | 1 |
Entamoeba histolytica | 3-oxoacyl-(acyl-carrier protein) reductase, putative | 0.0261 | 0.061 | 0.5 |
Echinococcus granulosus | 3 oxoacyl acyl carrier protein reductase | 0.0261 | 0.061 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0261 | 0.061 | 1 |
Echinococcus multilocularis | 3 oxoacyl acyl carrier protein reductase | 0.0261 | 0.061 | 1 |
Trypanosoma cruzi | oxidoreductase-like protein, putative | 0.0266 | 0.0623 | 1 |
Toxoplasma gondii | 2,4-dienoyl CoA reductase 2, peroxisomal family protein | 0.0266 | 0.0623 | 0.0013 |
Wolbachia endosymbiont of Brugia malayi | enoyl-ACP reductase | 0.3854 | 1 | 1 |
Echinococcus multilocularis | Ankyrin | 0.0028 | 0.0001 | 0.001 |
Mycobacterium ulcerans | short-chain type dehydrogenase/reductase | 0.0266 | 0.0623 | 0.0013 |
Echinococcus granulosus | nuclear factor of activated T cells 5 | 0.014 | 0.0295 | 0.4838 |
Brugia malayi | oxidoreductase, short chain dehydrogenase/reductase family protein | 0.0261 | 0.061 | 1 |
Trypanosoma brucei | oxidoreductase-like protein | 0.0266 | 0.0623 | 1 |
Echinococcus granulosus | Ankyrin | 0.0028 | 0.0001 | 0.001 |
Mycobacterium tuberculosis | Probable oxidoreductase | 0.0338 | 0.0812 | 0.0214 |
Mycobacterium leprae | NADH-DEPENDENT ENOYL-[ACYL-CARRIER-PROTEIN] REDUCTASE INHA (NADH-DEPENDENT ENOYL-ACP REDUCTASE) | 0.3854 | 1 | 1 |
Plasmodium falciparum | enoyl-acyl carrier reductase | 0.3854 | 1 | 1 |
Mycobacterium ulcerans | 3-alpha-hydroxysteroid dehydrogenase | 0.0266 | 0.0623 | 0.0013 |
Leishmania major | pteridine reductase 1 | 0.0266 | 0.0623 | 1 |
Schistosoma mansoni | retinoblastoma-binding protein 4 (rbbp4) | 0.0028 | 0.0001 | 0.001 |
Brugia malayi | oxidoreductase, short chain dehydrogenase/reductase family protein | 0.0261 | 0.061 | 1 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
2 literature references were collected for this gene.